Published in final edited form as:

J Trauma Acute Care Surg. 2014 December ; 77(6): 938–943. doi:10.1097/TA.0000000000000352.

Alcohol Withdrawal Syndrome in Critically Ill Patients: Protocolized vs Non-Protocolized Management

Jeremiah J. Duby, Pharm.D. [Senior Critical Care Pharmacist, Specialty Critical Care Resident Program Director, Assistant Clinical Professor Touro University],
University of California Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA 95817, UCSF
College of Pharmacy, UC Davis School of Medicine dubyjj@gmail.com

Andrew J. Berry, Pharm.D., BCPS [Clinical Pharmacy Specialist],
Cardiology Banner Good Samaritan Medical Center, Phoenix, AZ,
Andrew.berry@bannerhealth.com

Paricheh Ghayyem, Pharm.D., BCPS [Inpatient Pharmacist],
UC San Diego Thornton Medical Center, La Jolla, CA Pghayyem@gmail.com

Machelle D. Wilson, PhD [Senior Statistician], and
Clinical & Translational Science Center, Department of Public Health Sciences, University of
California Davis, 2921 Stockton Blvd, Suite 1400, Sacramento, CA 95817, Office: (916)
703-9106, mdwilson@phs.ucdavis.edu

Christine S. Cocanour, M.D.* [Professor]
University of California Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA 95817,
Professor, Department of Surgery, Division of Trauma and Emergency Surgery Services

Abstract

BACKGROUND—Approximately 18–25% of patients with alcohol use disorders admitted to the hospital develop alcohol withdrawal syndrome (AWS). Symptom-triggered dosing of BZDs appears to lead to shorter courses of treatment, lower cumulative BZD dose and more rapid control of symptoms in non-critically ill patients. This study compares the outcomes of critically ill patients with AWS when treated using a protocolized, symptom-triggered, dose-escalation approach versus a non-protocolized approach.

METHODS: This is a retrospective pre-post study of patients 18 years with AWS admitted to an ICU. The PRE cohort (PRE) was admitted between 2-2008 and 2-2010. The Post-intervention cohort (POST) was admitted between 2-2012 and 1-2013. PRE were treated by physician preference and compared to POST that were given escalating doses of BZDs and/or phenobarbital according to an AWS protocol, titrating to light sedations (RASS of 0 to –2).

*Corresponding author, Christine.cocanour@ucdmc.ucdavis.edu.

Partial results were presented at SCCM Annual Congress, Houston, Tx (Feb 4–8th, 2012) Complete study presented at Western Trauma Association, Steamboat Springs, CO; March 2–7, 2014

Author Contribution: All authors were involved with the literature search, study design, data collection, data analysis, data interpretation, writing and critical revision

This manuscript includes the unlabeled use of benzodiazepines, phenobarbital and dexmedetomidine for alcohol withdrawal syndrome.

RESULTS: There were 135 episodes of AWS in 132 critically ill patients. POST (n=75) were younger (50.7 ± 13.8 vs 55.7 ± 8.7 years, $p=0.03$) than PRE (n=60). SOFA scores were higher in PRE (6.1 ± 3.7 vs 3.9 ± 2.9 , $p=0.0004$). There was a significant decrease in mean ICU LOS from 9.6 ± 10.5 to 5.2 ± 6.4 days ($p=0.0004$) in the POST group. The POST group also had significantly fewer ventilator days (5.6 ± 13.9 vs 1.31 ± 5.6 days, $p<0.0001$) as well as a significant decrease in BZD usage (319 ± 1084 vs 93 ± 171 mg, $p=0.002$). There were significant differences between the two cohorts with respect to need for continuous sedation ($p<0.001$), duration of sedation ($p<0.001$), and intubation secondary to AWS ($p<0.001$). In all of these outcomes, the POST cohort had a notably lower frequency of occurrence.

CONCLUSION—A protocolized treatment approach of AWS in critically ill patients involving symptom-triggered, dose escalations of diazepam and phenobarbital may lead to a decreased ICU LOS, decreased time spent on mechanical ventilation, and decreased BZD requirements.

Keywords

Alcohol Withdrawal Syndrome; benzodiazepines; sedation; ICU

Background

Alcohol use is common in the United States. More than half of all Americans over the age of 12 self-report to be current drinkers and 18.6 million (7.4%) admit dependence on alcohol.¹ Approximately 18-25% of patients with alcohol use disorders admitted to the hospital develop alcohol withdrawal syndrome (AWS).² Alcoholism is associated with increased risk of nosocomial infection, sepsis, length of stay, and mortality in critically ill patients.²

Although no formal guidelines are published, benzodiazepines (BZDs) are widely accepted as first line treatment for AWS.³ Historically, BZDs have been administered in a continuous or scheduled fashion and gradually tapered following a 5- to 7- day course. However, two studies in non-critically ill hospitalized patients found that those who received symptom-triggered dosing of BZDs had similar outcomes to those who received scheduled BZDs, but required shorter courses of treatment and lower cumulative BZD doses.^{4,5} In patients admitted to an ICU solely for treatment of AWS, a symptom-triggered strategy of escalating doses of BZDs in combination with phenobarbital resulted in a significant decrease in need for mechanical ventilation and a trend toward decreased ICU length of stay and rate of nosocomial pneumonia.⁶ Most studies of AWS only included critically ill patients admitted for AWS and explicitly excluded patients with other acute problems or major comorbidities that are common in the ICU.^{2,6,7}

These evidence-based elements of AWS management were incorporated into a protocol that applied a symptom-triggered, dose-escalation approach using BZDs and phenobarbital. An agitation sedation scoring system was used to direct bedside dosing and monitoring. The purpose of this study was to compare patient outcomes in critically ill patients with AWS, regardless of their admission ICU diagnosis, that were treated with this protocolized approach versus a non-protocolized approach.

Methods

This single-center, pre-post study was conducted in adult patients with AWS admitted to the ICU at an urban, academic tertiary referral center. The institutional review board approved the study and waived the need for informed consent. Patients in the Pre-intervention group (PRE) were treated in a non-protocolized fashion and typically received continuous infusions or scheduled doses of BZDs per physician preference. Patients in the Post-intervention group (POST) were given escalating doses of diazepam and phenobarbital according to an AWS protocol (Figure 1) which was available via an electronic order set. Patients received symptom-triggered doses of diazepam every 15 to 30 minutes until target sedation level was achieved. Target sedation level was defined as a Richmond Agitation Sedation Scale (RASS) of 0 to -2 which corresponds to light sedation.⁸ Nurses were directed to continue escalating diazepam doses up to a maximum of 120mg. Phenobarbital was included in the protocol as an adjunct to be given every 30 minutes in a similar dose escalation fashion up to a maximum of 240mg.

Subjects in the PRE group were identified from electronic medical records by automated reports capturing patients by ICD-9 code—alcohol withdrawal (291.81), unspecified alcohol dependence (303.90) and alcohol dependence with continuous drinking behavior (303.91). Subjects for the POST group were consecutively admitted patients that received orders for the AWS order set. A search of the electronic medical record for concurrent use of thiamine and folate was used to supplement and capture potential patients in both PRE and POST groups. Patients were included if AWS was identified as a diagnosis in the history and physical or a progress note.

Patients were included that were 18 years of age or older and admitted to an ICU between February 2008 and February 2010 (PRE) or between February 2012 and January 2013 (POST). A primary diagnosis of AWS was not required for study inclusion. However, patients were characterized according to the primary reason for ICU admission, ie AWS or another diagnosis. Patients with all other comorbidities were deliberately included with the exception of severe brain injury—defined as persistent Glasgow Coma Score < 8—due to the inability to fully assess withdrawal symptoms and sedation levels in these patients.

The primary outcome measure was ICU length of stay. Secondary outcomes included mean and median BZD use, mean and median phenobarbital use, duration of sedation, requirement for mechanical ventilation (MV), ventilator-free days, and requirement for MV due to AWS. BZD usage was measured in lorazepam equivalents using the following formula: 5 mg diazepam = 1 mg lorazepam equivalents, 2 mg midazolam = 1 mg lorazepam equivalents.⁹ Baseline patient characteristics were collected to determine severity of illness and severity of AWS in the study population. Ventilator-free days were defined as the number of days of unassisted breathing to day 28. Patients that died were considered to have zero ventilator-free days.

To avoid over-fitting while at the same time using care to control for confounding variables, we used a two-phase model selection process. First we performed a series of univariate tests to see how various patient characteristics and risk factors differed between the PRE and

POST patients. Any variables which were significant at the 0.1 level or lower were included for further testing. Next, for the continuous response variables, time on ventilator, ICU length of stay, and ventilator-free days, a multiple linear regression was fit using a SAS® software backward selection procedure GLMSELECT using the variables from the previous phase. The full model included the explanatory variables admission secondary to AWS, phenobarbital usage, diazepam usage, age, duration of sedation, and SOFA score. The selection criterion used was the optimized Schwarz Bayesian Information Criterion. For the binary variables, death, requiring intubation, seizures while admitted, requiring continuous sedation, multiple logistic regression was fit using a SAS® software backward selection procedure LOGISTIC. The selection criterion used was a p-value of less than 0.05.

Results

There were 135 episodes of AWS in 132 critically ill patients. The majority of these patients were treated by the medical ICU (~50%) or trauma surgery services (~30%). The remaining patients were treated by orthopedic surgery, ENT, burn, transplant, cardiology, neurosurgery, and general medicine services.

Demographic information is found in Table 1. There were significant differences between PRE and POST groups in age, and SOFA score. Compared to the PRE group, the POST group was significantly younger with a mean age of 50.7 ± 13.8 versus 55.7 ± 8.7 years, respectively ($p=0.03$). SOFA scores upon ICU admission for the PRE versus POST group were 6.1 ± 3.7 and 3.9 ± 2.9 , respectively ($p=0.0004$).

Table 2 shows both primary and secondary outcomes. There was a significant difference between the two groups in the primary outcome of ICU LOS, 9.6 ± 10.5 days in the PRE group versus 5.2 ± 6.4 days in the POST group ($p=0.0004$). There was insufficient evidence of an effect due to any of the variables other than duration of sedation and the use of the protocol. There was weak evidence of an effect due to the use of the protocol ($p=0.096$). There was overwhelming evidence of an effect due to duration of sedation. The ICU LOS increased 0.7 days for each additional day of sedation ($p<0.0001$).

Mean sedative use is shown in Figure 2. There was a substantial decrease in mean BZD usage between the two groups with POST group patients requiring less than a third of total BZD compared to the PRE group ($p=0.0002$). The medians showed a trend towards less BZD use between PRE and POST groups (33 mg vs 23 mg, $p=0.06$). Mean phenobarbital usage increased in the POST group ($p=0.04$). Very few patients required phenobarbital in either PRE or POST groups and the medians were zero for each. The POST group had significantly less need for continuous sedation and duration of sedation. See Table 2. There was a strong link between SOFA score and the need for continuous sedation based on multivariate regression analysis. For every unit increase in the SOFA score, the odds of requiring continuous sedation increased by about 36% ($p<0.0001$).

The PRE group required almost 5 days more in time on the ventilator than the POST group (5.6 ± 13.9 versus 1.31 ± 5.6 days, $p<0.0001$). This is also reflected in a significant increase in the number of ventilator-free days in the POST group ($p=0.0004$). The need for

intubation due to AWS was significantly reduced in the POST group (22% vs 5%, $p < 0.001$). After controlling for severity of illness with multi-variate regression analysis, every additional day of sedation was associated with an additional 0.53 days on the ventilator ($p < 0.0001$). Similarly, after controlling for duration of sedation, the average time on the ventilator increased 0.61 days for each unit increase in *SOFA* score ($p = 0.01$). There was very strong evidence of an effect due to BZD on the number of ventilator-free days. There was also strong evidence that patients admitted primarily for AWS were at higher risk for intubation--due to AWS--than patients admitted for another critical illness ($p = 0.04$). Patients in the PRE group were at a greater risk for intubation than POST group patients ($p = 0.02$). Increased *SOFA* scores were associated with an increased risk for intubation ($p < 0.0001$).

Seven patients (11.6%) in the PRE group died during their hospitalization, while two patients in the POST group (2%) died ($p = 0.07$). None of these deaths were directly attributable to AWS. Increasing *SOFA* scores was directly associated with an increased risk of death ($p = 0.0002$). For every unit increase in *SOFA* score the odds of death increased by 61%. There was insufficient evidence of an effect due to any of the other variables tested.

Discussion

This study compared protocolized treatment of AWS to non-protocolized care. An alcohol withdrawal order set developed for the electronic medical record facilitated high level of concordance with the protocol. The key elements of the protocol were based on Gold's symptom-triggered, dose-escalation approach using BZDs and phenobarbital.⁶ There were a number of unique features in the design and execution of this study. In contrast to most studies of the treatment of AWS,^{6,7,10,11,12} this study included all patients with AWS regardless of primary diagnosis upon admission. The improvement in patient outcomes seen supports the use of this management strategy in all types of ICU patients, not just those admitted for AWS.

A critically ill patient with AWS can strain ICU resources. They often require one-to-one nursing and sedation requirements can be enormous. This protocol was developed to equip the bedside nurse to monitor the patient and administer sedation using a sedation assessment tool and a symptom-triggered approach. The Clinical Institute Withdrawal Assessment (CIWA-Ar)¹³ is not useful in most ICU patients for a number of reasons that include the following. It requires cooperation and communication on the part of the patient which eliminates those patients that are delirious or intubated. Parameters are subjective and very labor intensive, taking at least 5-15 minutes to complete. CIWA-Ar scores may be confounded by comorbidities such as trauma or critical illness. CIWA-Ar is not an effective treatment monitor for ICU patients as it was essentially developed to triage patients based on severity of alcohol withdrawal. In the study protocol, CIWA-Ar is used for determining the patient's risk of developing severe AWS and need for ICU management. Previous studies have demonstrated the difficulty of serial assessment using CIWA-Ar.^{14,15} RASS was selected for treatment monitoring because our institution already uses it for sedation assessment. It can be performed easily and quickly, and is similar to other sedation assessment tools, eg Ramsey, Riker Sedation-Agitation Scale. The main advantage of basing

therapy on a sedation assessment tool is that the bedside nurse can seamlessly assess the symptom and response with the same tool.

There were two key differences between the PRE and POST patients. The PRE group was older, which may signal the probability of more comorbidities, and their SOFA score on admission was higher. Although the SOFA score indicates that the PRE group was sicker, the difference may be due in part to the differences in management between the PRE and POST groups. In the PRE group, the increased need for intubation for AWS and consequent use of sedation may have driven the SOFA score higher. Intubation and change in Glasgow Coma Score from sedation could easily account for a two-point difference in SOFA score. Despite this possibility, there were still differences in the clinical outcomes favoring the POST group after controlling for age and severity of illness with regression analysis.

The substantial reduction in ICU LOS and duration of sedation between the two groups suggests that early, aggressive, symptom-triggered dosing of diazepam and phenobarbital can obtain rapid relief of symptoms, lead to shorter courses of therapy and reduce the need for intubation. These benefits were noted previously in critically ill patients with AWS,^{6,10} but to our knowledge they have never been shown simultaneously in a single study. Gold et al also noted a statistically significant reduction in the need for intubation following the implementation of, “guidelines emphasizing escalating doses of diazepam in combination with phenobarbital”. Additionally, a trend in reduction in ICU LOS was noted between groups.⁶ However, in our study, ICU LOS was significantly decreased in POST patients which may be related to significantly less time on the ventilator. It is well established that intubation is associated with longer hospital stay and higher rates of nosocomial pneumonia. Therefore, it is logical to suggest that decreasing the use of mechanical ventilation by using symptom-triggered bolus dosing of BZDs and phenobarbital will lead to decreased LOS and decreased nosocomial pneumonia in previous studies.^{6,11} Additionally, there was a trend towards decreased mortality in the POST group which may be related to the decreased need for intubation and time on the ventilator or it could be related to the difference in SOFA score on admission.

Another factor that may have played a role in the decrease in ICU LOS is the decreased use of continuous infusions in the POST group. Limited data suggest that intermittent-bolus dosing of medications may be superior to continuous infusion for AWS,¹¹ an assertion supported by our study. Benzodiazepine exposure was notably lower in the POST group relative to the PRE group. Providing escalating BZD doses, guided by RASS scores, allows nurses to target patient-specific benzodiazepine needs. The ability to quickly and effectively target an individual patient's required sedative dose allows for a shorter duration of sedation, as demonstrated by previous studies.^{4-7,11} Patients with severe AWS that receive escalating, intermittent doses of BZD do not experience escalation of symptoms when controlled early and effectively in contrast to those treated with continuous sedation. On the other hand, patients with mild AWS symptoms are spared a scheduled dosing regimen when they potentially require minimal BZDs to reach a targeted sedation level. In our study, a third of both PRE and POST groups required 10 mg or less of BZD. The increase seen in phenobarbital usage in the POST group is explained by its presence on the protocol which led to more wide spread use (3% versus 13%).

BZDs are the currently accepted treatment of choice for AWS, although some have advocated for bolus doses of phenobarbital as first-line treatment.¹⁶⁻¹⁸ However, phenobarbital is more often added as an adjunct to BZDs for those patients requiring large doses of BZD and who remain agitated.^{6,19} In our protocol, BZDs were chosen over other available therapeutic agents due to their low cost. Although reserved for refractory cases of AWS, dexmedetomidine may also serve as another useful, adjunctive agent for AWS.²⁰⁻²² Other adjunctive agents such as beta blockers or clonidine may be employed for AWS, but there is insufficient evidence to support their general use.

The limitations of this study include its retrospective, single-center design. Although there are disadvantages of a pre-post study design when compared to a randomized control trial, it does demonstrate this strategy may be executed using resources commonly available in the ICU such as a sedation assessment tool and BZDs. Because of its retrospective nature, potential differences between groups may not have been identified or controlled for. Potential confounders included varied AWS management strategies in the PRE group, withdrawal from other illicit drugs, and differences in ICU management. Age and severity of illness were significantly different between the two groups. To control for these explanatory variables, regression analysis was performed for the primary and secondary outcomes.

Conclusions

This study suggests that a protocolized treatment approach using early, aggressive, symptom-triggered dosing of diazepam and phenobarbital is associated with decreased need for intubation, less time on mechanical ventilation, ICU LOS, reduced BZD exposure and possibly decreased mortality.

Acknowledgments

Funding Sources: The statistical analysis was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through grant #UL1 TR000002.

References

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD.: 2010. (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings)
2. De Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. *Chest*. 2010; 138(4):994–1003. [PubMed: 20923804]
3. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. *CMAJ*. 1999; 160(5):649–55. [PubMed: 10101999]
4. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. *JAMA*. 1994; 272(7):519–23. [PubMed: 8046805]
5. Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S, Yersin B. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. *Arch Intern Med*. 2002; 162(10):1117–21. [PubMed: 12020181]
6. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. *Crit Care Med*. 2007; 35(3):724–30. [PubMed: 17255852]

7. Mueller SW, Preslaski CR, Kiser TH, Fish DN, Lavelle JC, Malkoski SP, MacLaren R. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. *Crit Care Med*. Dec 17.2013 [Epub ahead of print].
8. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med*. 2002; 166:1338–44. [PubMed: 12421743]
9. Dundee JW, McGowan WAW, Lilburn JK, McKay AC, Hegarty JE. Comparison of the actions of diazepam and lorazepam. *Br J Anaesth*. 1979; 51:439–445. [PubMed: 36117]
10. DeCarolus DD, Rice KL, Ho L, Willenbring ML, Cassaro S. Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit. *Pharmacotherapy*. 2007; 27(4):510–8. [PubMed: 17381377]
11. Spies CD, Otter HE, Hüske B, Sinha P, Neumann T, Rettig J, Lenzenhuber E, Kox WJ. Alcohol withdrawal severity is decreased by symptom-oriented adjusted bolus therapy in the ICU. *Intensive Care Med*. 2003; 29(12):2230–8. [PubMed: 14557857]
12. Ng K, Dahri K, Chow I, Legal M. Evaluation of an alcohol withdrawal protocol and a preprinted order set at a tertiary care hospital. *Can J Hosp Pharm*. 2011; 64(6):436–445. [PubMed: 22479099]
13. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). *Br J Addict*. 1989; 84(11):1353–7. [PubMed: 2597811]
14. Hecksel KA, Bostwick JM, Jaeger TM, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. *Mayo Clin Proc*. 2008; 83(3):274–9. [PubMed: 18315992]
15. Bostwick JM, Lapid MI. False positives on the Clinical Institute Withdrawal Assessment for Alcohol—Revised: is this scale appropriate for use in the medically ill? *Psychosomatics*. 2004; 45(3):256–261. [PubMed: 15123853]
16. Young GP, Rores C, Murphy C, Dailey RH. Intravenous phenobarbital for alcohol withdrawal and convulsions. *Ann Emerg Med*. 1987; 16(8):847–50. [PubMed: 3619162]
17. Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. *Am J Emerg Med*. May. 2011; 29(4):382–5. [PubMed: 20825805]
18. Michaelsen IH, Anderson JE, Fink-Jensen A, Allerup P, Ulrichsen J. Phenobarbital versus diazepam for delirium tremens - a retrospective study. *Dan Med Bul*. 2010; 57(8):A4169.
19. Hayner CE, Wuestefeld NL, Bolton PJ. Phenobarbital treatment in a patient with resistant alcohol withdrawal syndrome. *Pharmacotherapy*. 2009; 29(7):875–8. [PubMed: 19558262]
20. Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. *Anesthesiology*. 2003; 98(2):575–7. [PubMed: 12552220]
21. Rovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoiki R. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. *Gen Hosp Psychiatry*. 2006; 28(4):362–3. [PubMed: 16814639]
22. Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. *Ann Pharmacother*. 2008; 42(11):1703–5. [PubMed: 18780809]

Figure 1.

Alcohol withdrawal protocol based on a symptom-triggered, dose-escalation approach using BZDs and phenobarbital. RASS is used for monitoring and administering sedation. BZD: benzodiazepine; RASS: Richmond Agitation Sedation Scale

Figure 2. Mean BZD and PB use in both PRE and POST groups. Means are presented as Mean $\pm$ SD
BZD: benzodiazepine; PB: phenobarbital

Table 1

Baseline characteristics of both PRE and POST groups.

	PRE group (n=60)	POST group (n=75)	P-value
Mean Age	55.7 ± 8.7 yrs	50.7 ± 13.8 yrs	0.03
Male	81.6%	81.3%	1.0
History of Alcohol Withdrawal	40%	30.6%	0.28
History of Psychosis	10%	12%	0.78
History of Delirium Tremens	10%	4%	0.19
History of Seizure	18.3%	21%	0.83
Mean SOFA score on admit	6.1 ± 3.7	3.9 ± 2.9	0.0004
Mean blood alcohol level on admit (mg/dL)	135 ± 156	134 ± 140	0.56

Means are presented as Mean ± SD

Table 2

Primary and Secondary Outcomes

	PRE group (n=60)	POST group (n=75)	P-value
ICU LOS	9.6 ± 10.5	5.2 ± 6.4	0.0004
Time on Ventilator (days)	5.6 ± 13.9	1.31 ± 5.6	<0.0001
Ventilator-free days	21.3 ± 9.5	26.3 ± 5.6	0.0004
Intubation due to AWS	13 (22%)	4 (5%)	<0.001
Need for continuous sedation	33 (55%)	18 (24%)	<0.001
Duration of sedation (days)	10.8 ± 8.9	3.5 ± 3.5	<0.001
Death	7 (12%)	2 (3%)	0.07

Means are presented as Mean ± SD

ICU LOS: intensive care unit length of stay; AWS: alcohol withdrawal syndrome